GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Accelerated Pharma Inc (NAS:ACCP) » Definitions » Total Tax Payable

Accelerated Pharma (Accelerated Pharma) Total Tax Payable : $0.00 Mil (As of Mar. 2017)


View and export this data going back to 2016. Start your Free Trial

What is Accelerated Pharma Total Tax Payable?

Accelerated Pharma's Total Tax Payable for the quarter that ended in Mar. 2017 was $0.00 Mil.


Accelerated Pharma Total Tax Payable Historical Data

The historical data trend for Accelerated Pharma's Total Tax Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Accelerated Pharma Total Tax Payable Chart

Accelerated Pharma Annual Data
Trend Dec14 Dec15 Dec16
Total Tax Payable
- - -

Accelerated Pharma Quarterly Data
Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17
Total Tax Payable Get a 7-Day Free Trial - - - - -

Accelerated Pharma Total Tax Payable Calculation

Total Tax Payable is the taxes liability owed to federal, state, and local tax authorities. It is the carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes.


Accelerated Pharma Total Tax Payable Related Terms

Thank you for viewing the detailed overview of Accelerated Pharma's Total Tax Payable provided by GuruFocus.com. Please click on the following links to see related term pages.


Accelerated Pharma (Accelerated Pharma) Business Description

Traded in Other Exchanges
N/A
Address
Website
Accelerated Pharma Inc, is a Delaware corporation organized on May 12, 2014. It is a biopharmaceutical company focused on utilizing its genomic technology to enhance the development and commercialization of pharmaceutical products. Its lead product candidate is Picoplatin, a new generation platinum-based cancer therapy that has the potential for use in different formulations, as a single agent or in combination with other anti-cancer agents, to treat multiple cancer indications.

Accelerated Pharma (Accelerated Pharma) Headlines

No Headlines